GlassScriptPhysician profile
Ankur Mishra
NPI 1619223880
$3,486.28
in general payments reported to CMS, 2019-2025
16 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $528 · 2021: $631 · 2022: $368 · 2023: $278 · 2024: $125 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,192.80 | 2019-2023 | Xarelto |
| Vifor Pharma, INC. | $409.40 | 2019-2022 | |
| Allergan, INC. | $242.55 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $239.26 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.97 | 2019-2020 | |
| Edwards Lifesciences Corporation | $213.09 | 2025 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $174.44 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $129.80 | 2019 | |
| Horizon Therapeutics Plc | $123.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.91 | 2021 | |
| Melinta Therapeutics, LLC | $96.97 | 2023 | Kimyrsa |
| Actelion Pharmaceuticals US, INC. | $96.80 | 2019 | |
| Fresenius USA Marketing, INC. | $85.92 | 2019 | |
| Sk Life Science, INC. | $49.82 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $17.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.